Literature DB >> 15188638

[Successful treatment of Weber-Christian panniculitis with cyclosporin-A].

Mónika Kovács1, János Hafner, Valéria Gábor, József Sipos.   

Abstract

The inflammatory disease of the subcutaneous fatty tissue are called panniculitis. The panniculitis has got a septal and a lobular histopathologic type. In the opinion of the etiologic classification occurs idiopathic (primary) or secondary entity. The secondary illnesses develop as the result of physical, chemical, biochemical, immunological, degenerative and proliferative reactions. In a part of panniculitis the etiologic factor is unknown. The authors demonstrate a rare type of the panniculitis, the Weber-Christian syndrome. This disease is an acute relapsing panniculitis with unknown etiology, fever, general symptoms and typical subcutaneous nodes. In their case the histological examination of the subcutaneous node resulted in non-suppurative, lobular panniculitis. The oral metilprednisolon and the occurring twice parenteral cyclophosphamide treatment had been proved to be unsuccessful, for this reason they started cyclosporin A therapy. Because of the cyclosporin A treatment the subcutaneous nodes regressed, the general symptoms ceased and the pathological laboratory findings became normal. The patient is asymptomatic under permanent therapy now. The authors discuss the differential diagnostic of this illness and the ways of treatments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15188638

Source DB:  PubMed          Journal:  Orv Hetil        ISSN: 0030-6002            Impact factor:   0.540


  2 in total

1.  Weber-Christian disease presenting with intractable fever and periorbital swelling mimicking angioedema.

Authors:  H P Wang; C C Huang; C H Chen; H Y Lin
Journal:  Clin Rheumatol       Date:  2006-03-21       Impact factor: 3.650

2.  A patient with Pfeifer-Weber-Christian disease--successful therapy with cyclosporin A: case report.

Authors:  Georg Pongratz; Boris Ehrenstein; Wolfgang Hartung; Jürgen Schölmerich; Martin Fleck
Journal:  BMC Musculoskelet Disord       Date:  2010-01-27       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.